Phase I evaluation of pharmacokinetics and tolerability of the HIV‐1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults

AIMS: GSK3640254, a novel, next‐generation maturation inhibitor effective against a range of HIV polymorphisms with no cross‐resistance to current antiretroviral therapy, could potentially be coadministered with dolutegravir as a 2‐drug regimen. In this phase I study, pharmacokinetics and tolerabili...

Descripción completa

Detalles Bibliográficos
Autores principales: Pene Dumitrescu, Teodora, Joshi, Samit R., Xu, Jianfeng, Greene, Thomas J., Johnson, Mark, Butcher, Laurie, Zimmerman, Eric, Webster, Lindsey, Pham, Theresa T., Lataillade, Max, Min, Sherene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451875/
https://www.ncbi.nlm.nih.gov/pubmed/33533507
http://dx.doi.org/10.1111/bcp.14759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451875/
https://www.ncbi.nlm.nih.gov/pubmed/33533507
http://dx.doi.org/10.1111/bcp.14759

Ejemplares similares